In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck,GSK co-develop antidepressant, deal ended

Executive Summary

GlaxoSmithKline licensed exclusive worldwide development and marketing rights to Merck KGAA's Phase II antidepressant EMD 68843 (vilazodone, a.k.a. SB 659746-A); Merck gets milestones and sales royalties, retains an option to co-promote outside of North America, and will manufacture the compound.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register